Biotechnology & Biosafety
Biotechnology & Biosafety — Containment Breach and Dual-Use Governance
A high-containment laboratory reports a potential exposure involving an enhanced pathogen.
Duration
120 min
Injects
5
Audience
Biosafety committee, research institution leadership, national regulator, public health
Situation
A high-containment (BSL-3/4) research facility reports a possible containment breach during work on an enhanced respiratory pathogen carried out under an approved research programme. A worker may have been exposed. The incident raises immediate biosafety questions and broader governance questions about oversight of research with pandemic-potential pathogens.
Exercise objectives
- Exercise incident response for a containment breach: exposure management, notification and transparency.
- Test institutional and national biosafety governance and reporting lines.
- Examine oversight of dual-use research of concern and research on pandemic-potential pathogens.
- Rehearse the balance between scientific openness, security and public trust.
Capability stress
How hard this scenario tests each of the 10 benchmark dimensions (1–5).
Foresight lens
Being able to cope with a threat that is precedent-free — a pathogen, dynamic or context we have NOT seen, where experience can actively mislead. Readiness is an adaptive capacity, not a plan for a known pattern.
TUNA profile
Assumptions this scenario windtunnelsfull register →
A6Existing biosecurity/biosafety oversight matches the pace of the science.
Sensitivity: high · TUNA: U · A · N
Scenario parameters
Illustrative planning figures for discussion — not operational data.
Facility
High-containment (BSL-3/4) research laboratory
Work
Approved programme involving an enhanced respiratory pathogen
Incident
Possible containment breach and worker exposure
Onward transmission risk
Depends on exposure; person-to-person plausible
Governance question
Adequacy of dual-use / pandemic-pathogen oversight
Roles at the table
Institutional Biosafety Officer
Leads the immediate incident response and internal reporting.
Institution Leadership
Owns disclosure, staff welfare and institutional accountability.
National Biosafety Regulator
Owns oversight, investigation and any suspension of work.
Public Health Lead
Manages worker health, contact assessment and any community risk.
Research Governance/Ethics Lead
Reviews the dual-use and pandemic-potential research question.
Inject timeline
- Hour 0Breach reported
A researcher reports a procedural failure with possible aerosol exposure.
- Hour 2Worker monitoring
The potentially exposed worker is placed under health monitoring; contacts assessed.
- Hour 8Regulator notified
The national regulator is informed and requests immediate documentation.
- Day 1Media enquiry
A journalist asks whether "gain-of-function" style work is done at the facility.
- Day 3Oversight question
Officials ask whether existing oversight of pandemic-potential research is adequate.
Decision points
D1How transparent is the institution about the breach and the nature of the research?
- Public trust and duty of candour vs. security and reputational concerns.
- What can be disclosed without creating misuse risk.
- Consistency between institutional and regulator messaging.
D2Should work of this type continue, pause, or face strengthened oversight?
- Scientific and public-health value of the research vs. residual risk.
- Whether current governance actually matched the risk of the work.
- Who has authority to suspend, and on what evidence.
Response playbook
Contain & care
- Secure the facility and the affected area
- Monitor and support the exposed worker
- Assess contacts
- Preserve incident records
Notify & investigate
- Report to the national regulator
- Launch a root-cause investigation
- Review the approval and oversight trail
- Coordinate communications
Govern & reform
- Decide on suspension or conditions
- Review dual-use oversight adequacy
- Publish appropriate findings
- Strengthen biosafety culture
After-action questions
- Did the oversight in place actually match the risk profile of the work?
- Who did the institution owe transparency to, and were those duties met?
- What is the right balance between scientific openness and misuse risk here?
National benchmark references
Real national strategies from the Global Pandemic Preparedness Benchmark that inform this scenario.